secondary outcomes, infants of mothers in the risk factor screening group were born marginally earlier than infants of mothers in the routine screening group (one trial, 3152 women, mean difference (MD) -0.15 weeks, 95% CI -0.27 to -0.03).
The remaining three trials evaluated different methods of administering a 50 g glucose load. Two small trials compared glucose monomer with glucose polymer testing, with one of these trials including a candy bar group. One trial compared a glucose solution with food. No differences in diagnosis of GDM were found between each comparison. However, in one trial significantly more women in the glucose monomer group screened positive for GDM than women in the candy bar group (80 women, RR 3.49, 95% CI 1.05 to 11.57). The three trials did not report on the primary review outcomes of mode of birth, large-for-gestational age or macrosomia. Overall, women drinking the glucose monomer experienced fewer side effects from testing than women drinking the glucose polymer (two trials, 151 women, RR 2.80, 95% CI 1.10 to 7.13). However, we observed substantial heterogeneity between the trials for this result (I² = 61%).
Authors' conclusions
There was insufficient evidence to determine if screening for gestational diabetes, or what types of screening, can improve maternal and infant health outcomes.
P L A I N L A N G U A G E S U M M A R Y

Screening for gestational diabetes and subsequent management for improving maternal and infant health
Gestational diabetes mellitus (GDM) is a form of diabetes that can develop during pregnancy. Having GDM increases the risk of complications during the rest of the pregnancy for the mother and her baby. Women with GDM are more likely to develop preeclampsia (high blood pressure and protein in the urine) and require a caesarean section. For the baby, potential problems include the baby growing larger than it normally would, causing difficulties with birth. The baby can also have low blood sugar levels after birth. Although GDM usually resolves following birth, both mother and child are at risk of developing type II diabetes in the future. There is strong evidence that treating GDM is beneficial and improves health outcomes.
It may therefore help if pregnant women are screened to identify as many as possible of those who do have GDM before they have symptoms, such as excessive thirst or urination, or fatigue. The two main approaches to screening are 'universal' where all women undergo a screening test for GDM; and 'selective' where only those women at 'high risk' are screened. The main risk factors are maternal age, high body mass index, family history and cigarette smoking. The different screening strategies used around the world to identify women with GDM include identifying women based on their risk factors, a blood sugar test one hour after a 50 g glucose drink, and random blood sugar measurements. It is however unclear whether screening for GDM leads to better health outcomes and if so, which screening strategy is the most appropriate.
This review included four trials involving 3972 women and their babies, and found that there is little high-quality evidence on the effects of screening for GDM on health outcomes for mothers and their babies. One trial compared risk factor screening with universal screening, and three trials evaluated different methods of administering a 50 g glucose load (the glucose load is used during the screening test). In one trial, women who were in the universal screening group were more likely to be diagnosed with GDM compared with women in the high-risk screening group. However, this trial was not of high quality. Few other differences between groups were shown in any of the trials. Further research is required to see which recommendations for screening practices for GDM are most appropriate.
B A C K G R O U N D Description of the condition
Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is defined as "carbohydrate intolerance of varying degrees of severity with onset or first recognition during pregnancy" (Metzger 1998) . GDM therefore includes type I or type II diabetes previously undetected or with first presenta-tion during pregnancy. GDM typically resolves following birth. However, these women are at risk for type II diabetes in the future (Kim 2002) .
Epidemiology
GDM affects up to 14% of pregnant women every year and accounts for 90% of pregnancies affected by diabetes mellitus (Coustan 1995; Setji 2005) . There is growing concern over the increasing prevalence of GDM and its effects for individual mothers and infants and its impact on public health (Ferrara 2007; Hunt 2007; Metzger 2007) . GDM is associated with numerous risk factors. Maternal age and body mass index (BMI) are among the most common risk factors (Di Cianni 2003; O'Sullivan 1973) . Specific ethnicities are also at higher risk of developing GDM, namely Hispanic, black, Native American, South or East Asian, Pacific Islander and Indigenous Australian (Kjos 2005) . These ethnicities are similar to those at high risk of type II diabetes mellitus, with suggestions that parallels may be drawn between these two forms of diabetes (Ben-Haroush 2004; Kuhl 1998) . Other risk factors include previous birth of a large baby, a family history of diabetes mellitus, weight gain and cigarette smoking (Davey 2001; Di Cianni 2003; O'Sullivan 1973; Solomon 1997) .
Aetiology/pathophysiology
Normally, insulin is released by pancreatic beta cells in response to increasing blood glucose levels to achieve euglycaemia (normal blood glucose levels). This system can be disrupted in two ways. A problem with the release of insulin from beta cells can occur, such as in type I or insulin dependent diabetes mellitus. Alternatively, insulin may not act as effectively in promoting glucose uptake. This is known as insulin resistance, and is seen in the development of type II or non insulin dependent diabetes mellitus and GDM. Placental hormones such as progesterone, cortisol, prolactin and human placental lactogen released mid-pregnancy contribute to decreased insulin action in pregnancy (Kuhl 1998) . Physiologically, this ensures sufficient nutrient transport to the fetus as it develops, and promotes growth (Setji 2005) . In a normal pregnancy, the action of these placental hormones is adequately compensated by increasing insulin release, creating an equilibrium between insulin supply and insulin demand. In pregnant women with abnormal glucose intolerance, the insulin resistance of pregnancy is not adequately compensated for, resulting in carbohydrate or glucose intolerance. It is suggested that women who develop GDM may also have an underlying insulin resistance, such as high maternal adiposity, or beta cell dysfunction that potentiates the insulin resistance of pregnancy (Buchanan 2005; Kuhl 1998; Richardson 2007) . Recent theories relating to the pathogenesis of GDM include inflammation (Richardson 2007) . These effects culminate in a disruption of the action of insulin in maintaining glucose levels, resulting in maternal hyperglycaemia (high blood glucose). Glucose is transferred, via the placenta, to the fetus. Maternal hyperglycaemia therefore stimulates a fetal hyperinsulinaemia to counter the excess placental glucose transfer. There is strong evidence confirming the continuum of risk associated with increasing carbohydrate intolerance (Dodd 2007; HAPO 2008; Sermer 1995) . The point at which this increasing carbohydrate intolerance becomes pathological remains uncertain.
Clinical features Infant
Excess insulin due to maternal hyperglycaemia acts in two ways on the fetus. Firstly, insulin promotes fat deposition due to the state of nutrient excess (Pedersen 1954; Whitelaw 1977) . Secondly, insulin acts as a growth factor, stimulating further growth of the infant in utero (Hunt 2007) . Thus, fetal hyperinsulinaemia results in excessive growth of the fetus, leading to one of the major perinatal concerns in GDM, macrosomia (birthweight greater than 4000 g). Macrosomia may lead to birth trauma including shoulder dystocia, nerve palsies and fractures (Dodd 2007; Metzger 1998) . GDM is associated with respiratory distress syndrome, neonatal hypoglycaemia (low blood glucose), hyperbilirubinaemia (high bilirubin levels), polycythaemia (excess red blood cells), and hypocalcaemia (low calcium) (ADA 2003; Metzger 1998) . In utero exposure to hyperglycaemia has long lasting effects on the infant, increasing their risk of future obesity and type II diabetes mellitus (Pettitt 1985; Silverman 1998) .
Maternal
With the implementation of screening protocols, GDM is usually diagnosed before it becomes symptomatic during pregnancy. However, where GDM is undetected, the pregnant woman may experience polyuria (increased urinary frequency), polydipsia (excessive thirst) or fatigue. Macrosomia in utero or polyhydramnios (excess amniotic fluid volume) may also indicate GDM. In the mother, evidence supports an association between GDM and increased rates of caesarean delivery and pre-eclampsia (ACOG 2001). As with their infants, the consequences of GDM for the mother extend beyond the perinatal period. There are strong links between GDM and future development of type II diabetes mellitus. Within 10 years of developing GDM, half the women develop type II diabetes mellitus (Kim 2002).
Diagnosis of GDM
Although diagnostic criteria vary (ACOG 2001; ADA 2003; Berger 2002; IADPSG 2010; NICE 2008; Oats 2004; RANZCOG 2008; WHO 1999) , the oral glucose tolerance test (OGTT) is considered the 'gold standard' for diagnosis of GDM (Scott 2002) . Minor degrees of abnormal carbohydrate tolerance, such as one abnormal value on OGTT or positive oral glucose challenge test (OGCT) with normal OGTT are also associated with similar outcomes to GDM. This is in line with the increasing awareness of the continuum of risk associated with increasing carbohydrate intolerance (Dodd 2007; HAPO 2008; Sermer 1995) .
Management of GDM
The importance of management for women with GDM has been widely accepted and is evaluated by several Cochrane reviews (Alwan 2009; Boulvain 2001; Ceysens 2006) and the treatment of GDM is widely supported (ADA 2003; Crowther 2005; Hoffman 1998; Metzger 1998; O'Sullivan 1966) . Treatment focuses on reducing the hyperglycaemia driving the complications of GDM (Metzger 1998). In general, management includes any or all of: nutritional therapy, exercise, blood glucose monitoring and insulin therapy. The results from two large, multi-centred randomised controlled trials provide strong support for the treatment of women with mild GDM (Crowther 2005; Landon 2009 ). Crowther and colleagues reported reduced infant morbidity in those treated for GDM in addition to suggesting that maternal quality of life was improved by treatment. Landon and colleagues showed treatment for GDM reduced the risks of fetal overgrowth, shoulder dystocia and pre-eclampsia.
Medical nutrition therapy
The American Diabetes Association and Australasian Diabetes in Pregnancy Society, in line with other governing bodies, recommend nutrition therapy in the treatment of GDM (ADA 2003; ADA 2007; Hoffman 1998) . Both guidelines focus on managing carbohydrate intake for blood glucose maintenance.
Exercise
Exercise is often used in conjunction with dietary therapy to maintain normal glucose levels. The Cochrane review 'Exercise in diabetic pregnancy' found that there was insufficient evidence to make a recommendation (Ceysens 2006) . However, there is growing consensus on the safety of moderate exercise in pregnancy and its benefits in the treatment of GDM.
Blood glucose monitoring
Blood glucose monitoring is often recommended (ACOG 2001; Hoffman 1998) . Postprandial hyperglycaemia monitoring demonstrates a closer association with rates of fetal macrosomia and obviously correlates with peaks of blood glucose (Hoffman 1998). Blood glucose monitoring provides the health professional with a representation of glycaemic control while providing the woman with feedback on her management progress.
Insulin/oral hypoglycaemic agents
Where the maternal hyperglycaemia cannot be managed by dietary or exercise advice and blood glucose levels remain elevated, insulin is added for greater control (Metzger 1998 
Birth
The Cochrane review 'Elective delivery in diabetic pregnant women' suggested that induction of labour at 38 to 39 weeks may be suitable for diabetic women treated with insulin (Boulvain 2001).
Following pregnancy
It is recommended that women whose pregnancies were affected by GDM receive an OGTT between six and 12 weeks postpartum to detect diabetes (ACOG 2009; Berger 2002; Hoffman 1998; Metzger 2007; Oats 2004; RANZCOG 2008) . Because of the high risk of future diabetes, these women are often advised to be retested on a regular basis (Hoffman 1998; Metzger 2007; Oats 2004; RANZCOG 2008) .
Description of the intervention Screening
A screening tool establishes the risk of disease in an otherwise well person (NSC 2007) . Ordinarily, the presentation of symptoms prompts testing for disease. However, screening aims to identify the illness earlier, before symptoms arise. Identification of an illness by screening allows for earlier management, which may result in better health outcomes. While screening can be beneficial, it can also cause unnecessary anxiety due to the testing process itself. This is further complicated by the occurrence of false positives, where screening has suggested an increased risk for the disease but the diagnostic test does not show evidence of the disease. An accepted screening process must first meet certain criteria (NSC 2003) . In addition to the illness being an important health problem, the screening process must benefit the individual. This includes the acceptability of the screening process clinically, socially and ethically and the availability of an effective treatment. These benefits must outweigh any possible harms such as discomfort from any testing and costs of administering the screening process. From an economic perspective, the screening process must also be cost effective.
Screening does not always involve a clinical test, and may include, for example, a series of history questions. Furthermore, it is important to distinguish screening from diagnostic procedures which provide a diagnosis in an already symptomatic or high-risk individual. It is important to distinguish between a screening and diagnostic test. While a screening test will identify those at risk for a disease, diagnostic tests are generally designed to give a definitive yes or no. Diagnostic tests are also often more complex and expensive than screening tests. While screening tools will identify those at risk of an illness, it is the subsequent management of the result that ultimately affects health outcomes. 'Screening' can be used to refer to an individual screening tool or to a screening program, protocol or guideline, which includes the screening tool and subsequent management such as diagnostic testing and treatment of any illness identified. By identifying individuals at high and low risk of a particular illness, a screening tool therefore identifies those who require diagnostic testing and those who do not. It therefore follows that the implementation of a screening program, which includes a combination of screening tool, subsequent diagnostic testing and management, is able to affect health outcome.
Screening for GDM
Whether to screen for GDM, and which methods to use, remain controversial. This is compounded by the lack of clearly defined, universally accepted screening criteria, and the uncertainty as to the severity of glucose intolerance at which treatment is beneficial. Even with screening protocols in place, GDM is diagnosed at the end of the second trimester or early third trimester based on physiology. This leaves little time for management of GDM. Without screening, the diagnosis of GDM, and therefore treatment, is potentially delayed. Screening for GDM is often implemented despite the uncertainty of its utility. A wide variety of strategies have been employed in screening for GDM that provide varying degrees of sensitivity and specificity. Universal or routine screening, usually where all women are offered a 50 g OGCT, and risk factor screening (by women's history) are the most commonly used methods and combinations of these and other methods have been used to form various screening protocols (ACOG 2001; Gabbe 2004; Metzger 2007; Mires 1999; Rumbold 2001) . The OGCT was originally proposed by O'Sullivan and colleagues to provide a more sensitive screening process than risk factor screening (O'Sullivan 1973 ). An OGCT involves a 50 g glucose drink and a blood glucose measurement after one hour. While the predefined risk factors used vary between centres and countries, they commonly include maternal age, BMI, ethnicity, previous GDM and family history of diabetes mellitus (ADA 2003; Berger 2002; Hoffman 1998; Metzger 2007; USPSTF 2008) .
Other methods used to screen for GDM include urine testing for glucosuria, fructosamine testing, random plasma glucose measurements, fasting plasma glucose measurements and HbA 1 c (a measure of how well blood glucose has been controlled over the previous two to three months) (Scott 2002) . The variation in screening protocols is reflected in surveys conducted around the world. In a UK survey of obstetric units in 1996, it was found that 89% screened for GDM, with 81% of those units using risk factor based screening (Mires 1999). There was a lack of consensus on the appropriate screening method (Mires 1999). In a similar Australian survey of obstetric practice conducted in 1999, it was found that 87% of the obstetric population was being screened for GDM. Again there was no strong consensus on how to screen (Rumbold 2001 ). An American survey in 2004 found that 95.2% of obstetricians screening for GDM adopted a universal one-hour 50 g OGCT (Gabbe 2004) . This diversity in preferred screening protocols may reflect a number of factors, such as the cost of screening, the expected prevalence of GDM and test accuracy, in addition to the lack of definitive evidence in favour of a particular screening protocol. A largely accepted time for screening is the end of the second trimester, ranging between 24 to 28 weeks' gestation (ACOG 2001; Hoffman 1998; Metzger 2007; Oats 2004; RANZCOG 2008) . This value reflects a balance between having adequate time to manage GDM and the ability to detect the development of carbohydrate intolerance (ACOG 2001; Brody 2003) . There is little evidence on the benefits and detriments of screening prior to 24 weeks' gestation (USPSTF 2008). The negative impact of screening for GDM also needs to be considered. The importance of identification of GDM should be weighed against any discomfort experienced by the woman and anxiety from testing. While the 50 g OGCT is considered to be a quick and simple test, it is unpleasant to drink and is associated with side effects such as dizziness, headaches, nausea and vomiting, and requires a blood test. For many women, the inconvenience of testing can be significant. Screening by any method can create anxiety for the mother, including women identified as having risk factors for GDM, those identified through routine OGCT and those with elevated random blood glucose levels. In particular, a false positive result has been associated with a decline in women's perception of health (Kerbel 1997; Rumbold 2002) . It also follows that with the introduction of screening, that more women are offered diagnostic testing, usually an OGTT, which requires them to fast overnight, drink a higher glucose load, requires more blood tests and can take up to three hours to complete. An evaluation of cost is imperative with any screening procedure. While screening processes may affect detection, management and therefore improve maternal and infant health, this must also be weighed against the cost of screening all pregnant women, any subsequent diagnostic tests and treatment for additional women diagnosed with GDM.
Many believe that the incidence of GDM, the adverse outcomes arising from GDM and the benefits of treatment suggest a need for some screening process. However, high-quality evidence demonstrating the effectiveness of screening on detection of GDM and subsequent maternal and infant health is required for screening to be implemented (NSC 2003) . Whether a screening protocol adequately identifies those at risk of GDM, and whether this knowledge improves the health outcomes for women with GDM and their babies through subsequent management of a screening result, are important factors to consider when recommending a screening process. It is also equally important that a recommended screening protocol does not harm women without GDM. Moreover, given the lack of consensus on a method for screening, an evaluation of the different screening protocols on the detection of GDM and subsequent maternal and infant health is required. This review updates a previously published Cochrane review on screening and subsequent management for GDM for improving maternal and infant health (Tieu 2010 
O B J E C T I V E S
To assess the effects of different methods of screening for gestational diabetes mellitus on maternal and infant outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, quasi-randomised controlled trials and cluster-randomised trials. We planned to exclude cross-over trials. We planned to include studies published as abstracts provided there was sufficient information to allow us to assess study eligibility and risk of bias. If sufficient information was not available, the study would await assessment pending the publication of the full trial report, or the provision of further information by trial authors.
Types of participants
Pregnant women, excluding women who have already been diagnosed with GDM in this pregnancy or who have pre-existing diabetes mellitus.
Types of interventions
Any individual screening tool or screening program, protocol or guideline for GDM compared with the absence of screening; or any individual screening tool or screening program, protocol or guideline for GDM with another.
Types of outcome measures Primary outcomes
Maternal
Perinatal
1. Diagnosis of GDM*; 2. positive screen for GDM*; 3. mode of birth (normal vaginal birth, operative vaginal birth, caesarean section).
Offspring
Neonatal
1. Large-for-gestational age (birthweight greater than or equal to 90th percentile); 2. macrosomia (greater than 4000 g or greater than 4500 g). * as defined by author(s) 5. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group. Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. We did not apply any language restrictions.
Data collection and analysis
For methods used in the previous version, please see Tieu 2010. For this update, the following methods were used.
Selection of studies
Two review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third review author. We entered data into Review Manager software (RevMan 2012) and checked for accuracy. When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved any disagreement by discussion or by involving a third author.
(1) Random sequence generation (checking for possible selection bias)
We described for each included study the methods used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We assessed the methods as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for each included study the method used to conceal the allocation sequence and determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias. We described for each included study, the methods, if any, used to blind study participants and personnel from knowledge of which intervention a participant received. We considered studies to be at a low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. We assessed the methods as: We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)
We described for each included study and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or was supplied by the trial authors, we included missing data in the analyses which we undertook. We assessed the methods as:
• low risk of bias (e.g. where there were no missing data or where reasons for missing data were balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);
(5) Selective reporting bias (checking for reporting bias)
We described for each included study how the possibility of selective outcome reporting bias was examined by us and what we found. We assessed the methods as:
• low risk of bias (where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review had been reported);
• high risk of bias (where not all the study's pre-specified outcomes had been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported);
(6) Other sources of bias (checking for bias due to problems not covered by (1) to (5) above)
We described for each included study any important concerns we had about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at a high risk of bias, according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses -see Sensitivity analysis.
Measures of treatment effect Dichotomous data
For dichotomous data, we presented results as risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference when outcomes were measured in the same way between trials. If necessary, we would have used the standardised mean difference to combine trials that measured the same outcome, but used different methods.
Unit of analysis issues Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses along with individually-randomised trials. We planned to adjust their sample sizes using the methods described in the Handbook using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we had used ICCs from other sources, we planned to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we had identified both cluster-randomised trials and individually-randomised trials, we planned to synthesise the relevant information. We would have considered it reasonable to combine the results from both if there was little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely.
We planned to also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.
Cross-over trials
We considered cross-over trials inappropriate for this research question.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial where the I² was greater than 30% and either the Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2011). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar. Where there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or where substantial statistical heterogeneity was detected, we used random-effects metaanalysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and we have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we would not have combined trials. Where we have used random-effects analyses, we have presented the results as the average treatment effect with its 95% confidence interval, and the estimates of Tau² and I²
Subgroup analysis and investigation of heterogeneity
If we had identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We planned to consider whether an overall summary was meaningful, and if it was, use random-effects analysis to produce it. We planned an assessment of trials comparing any screening protocol with none, with data analysed separately for different methods of screening. We analysed trials comparing one method of screening with another, with data from different comparisons analysed separately. We planned to carry out the following subgroup analyses for primary outcomes:
• high risk for GDM (variously defined) (we will explore risk factors individually if sufficient data become available);
• gestational age at screening (less than 24 weeks, 24 to 30 weeks, 30 weeks or more);
• number of stages in the screening protocol;
• type of management protocol.
There were insufficient data to conduct subgroup analyses. We planned to assess subgroup differences by interaction tests available in within RevMan (RevMan 2012). We planned to report the results of the subgroup analysis quoting the Chi² statistic and P value, and the interaction test I² value.
Sensitivity analysis
We planned to carry out sensitivity analysis to explore the effect of trial quality assessed by concealment of allocation, by excluding studies with clearly inadequate allocation of concealment (rated high risk of bias). We planned to then carry out sensitivity analysis to explore the effect of trial quality on primary outcomes. This would have involved analysis based on an assessment of selection bias and attrition bias. We planned to exclude studies of poor quality in the analysis (those rating unclear or high risk) in order to assess for any substantive difference in the overall result. There were insufficient data to conduct sensitivity analyses.
Description of studies Results of the search
The updated search of the Cochrane Pregnancy and Childbirth Group's Trials Register identified three studies (one which was awaiting assessment in the previous version of this review). We have excluded the three studies, and have therefore not included any new trials in this update. In the previous version of this review, the search identified 31 trials to be considered for inclusion. Following application of eligibility criteria, we included four of these trials in this review (Bergus 1992; Griffin 2000; Martinez Collado 2003; Murphy 1994) ; we excluded 25, and one remains awaiting classification (Bebbington 1999).
Included studies
One quasi-randomised study compared the effect of screening by risk factors and universal (routine) screening by a 50 g oral glucose challenge test (OGCT) on health outcomes (Griffin 2000) . In all studies, women were recruited from obstetric clinics. Gestational age at entry was specified in Bergus 1992 and Martinez Collado 2003, where women were between 24 and 28 weeks' gestation. Murphy 1994 screened women routinely at 24 to 28 weeks' gestation and also screened women at their first antenatal visit if they were found to have one of the following risk factors for GDM: past history of glucose intolerance, first-degree relative with diabetes mellitus, age greater than 35 years, previous baby with macrosomia, habitual abortion, unexplained stillbirth, congenital anomalies, current pregnancy with glycosuria, hypertension, suspected large-for-gestational-age fetus, polyhydramnios or obesity. Martinez Collado 2003 included women with a 'high-risk' pregnancy, although a description of 'high risk' was not reported. This trial excluded women with diabetes, previously diagnosed GDM and those treated with steroids or tocolytics. No other exclusion criteria were listed for the studies. Baseline characteristics of the participants by treatment group were compared in two studies (Griffin 2000; Murphy 1994) . In Murphy 1994, there was an imbalance in age and parity at screening with participants in the candy bar group being younger and having a lower parity than those in the d-glucose group. No baseline imbalances were reported between women in the candy bar group and the polymer group. Participants in the risk factor group and universal group in Griffin 2000 were similar with respect to age, weight at 36 weeks, BMI, gestational age at delivery, parity and prevalence of risk factors for GDM.
Interventions
Risk factor versus universal (routine) screening
Griffin 2000 compared risk factor screening with universal (routine) screening. Participants in the risk factor group of Griffin 2000 were screened on the basis of historical and current risk factors, including having a first-degree relative with diabetes mellitus, weighing more than 100 kg in the current pregnancy, having a previous baby greater than 4.5 kg, previous unexplained stillbirth or intrauterine death, previous major malformation, previous GDM, glycosuria in second fasting urine sample, macrosomia in the current pregnancy and polyhydramnios in the current pregnancy. Women received glucose testing by a 100 g oral glucose tolerance test (OGTT) at 32 weeks' gestation where they were found to have any of the risk factors listed. The universal screening group used a 50 g OGCT at 26 to 28 weeks' gestation. A one-hour plasma glucose of greater than or equal to 7.8 mmol/L was considered positive. A positive screening test was an indication for a full 100 g OGTT using the National Diabetes Data Group criteria for diagnosis. The 50 g OGCT was repeated in those with a negative OGCT and with risk factors for GDM four to six weeks after the initial OGCT. Women who were diagnosed with GDM were treated by standard diabetes management, maintaining otherwise similar antenatal care for both groups. Griffin 2000 referred women for obstetric and endocrinology review fortnightly and weekly after 36 weeks' gestation, with treatment including diabetic diet and insulin as required.
Glucose method
Bergus 1992, Martinez Collado 2003 and Murphy 1994 compared different methods of glucose loading as screening tests for GDM. Both Bergus 1992 and Murphy 1994 assessed solutions of glucose monomer (d-glucose) and glucose polymer. Murphy 1994 included an additional group where participants ate 50 g chocolate bars in place of a glucose drink. In both studies, all women underwent a glucose tolerance test within three to seven days of their 50 g challenge test. Both used a 100 g OGTT by O'Sullivan criteria to diagnose GDM. Martinez Collado 2003 compared a 50 g glucose solution with a food mix, which included 50 g of glucose, and did not report on further testing to diagnose GDM. It is not reported whether the glucose solution was a glucose monomer or polymer.
Outcomes
Griffin 2000 reported clinical measures of maternal health outcome and infant health outcome and size. Bergus 1992, Martinez Collado 2003 and Murphy 1994 focused primarily on the efficiency of the methods by which glucose was administered, reporting on diagnosis of GDM, glucose levels following testing and the adverse effects of the different methods. Murphy 1994 reported side effects only where they were rated moderate to severe by women on a five-point scale.
Excluded studies
Eighteen studies identified by the literature search assessed strategies for diagnosis of GDM rather than screening (Berkus 1995; Brustman 1995; Buhling 2004; Cheng 1992; Court 1984; Court 1985; Duenas-Garcia 2011; Fung 1993; Harlass 1991; Jones 1993; Meltzer 2010; Olarinoye 2004; Saijan 2011; Sammarco 1993; Soonthornpun 2003; Stavrianos 2004; Weiss 1998; Zhang 1995) . One study was not randomised (Dornhorst 2000) . Seven of the trials identified were cross-over studies (Eslamian 2007; Eslamian 2008; Helton 1989; Hidar 2001; Lamar 1999a; Lamar 1999b; Soonthornpun 2008) and two studies included women who had already undergone diagnostic testing for GDM (Kjos 2001; Lewis 1993) .
Risk of bias in included studies
Please see Figure 1 and Figure 2 for summaries of all 'Risk of bias' assessments. 
Incomplete outcome data
Ten out of 76 women (13%) did not complete the symptom questionnaire in Bergus 1992 and it is reported that their baseline characteristics were comparable to those who were followed up. Griffin 2000 reported that 590, or 31%, of the women in the universal screening group did not consent to glucose challenge testing and were excluded from analysis. No participants in the risk factor screening group were lost to follow-up. Routine care in this centre was risk factor screening, which contributes to the differential loss to follow-up rate. There were no significant differences between those who consented to glucose challenge testing and those who did not in Griffin 2000. Sixteen women in Murphy 1994 were lost to follow-up. However, no comparison of baseline characteristics of those lost to follow-up and those who remained in the study was made and it is unclear which groups these women were from. It is also uncertain as to how many women in Murphy 1994 were being screened in their first trimester or at 24 to 28 weeks' gestation.
Selective reporting
Outcome data in Griffin 2000 was analysed primarily by GDM diagnosis rather than by original group allocation by day of visit, which affects the ability to interpret results of pre-specified outcomes. Although a comparison of baseline characteristics between women who were able or unable to complete the symptom questionnaire was made, Bergus 1992 did not report the baseline characteristics of participants by intervention group. Murphy 1994 only reported side effects of testing where women had rated their symptoms as moderate or severe, equivalent to a three to five out of a possible five. Mild symptoms were unreported.
Other potential sources of bias
Analysis of Griffin 2000 was based on diagnosis of GDM rather than original group allocation by day of visit. Because no baseline comparison of the intervention groups was made in Bergus 1992 and Martinez Collado 2003, it is uncertain whether or not baseline imbalances are present.
Overall risk of bias
In general, assessment of the included studies for methodological quality revealed a moderate to high risk of bias, which is likely to have affected the results of the review (Figure 1; Figure 2 ) by making the results of trials less certain. Most studies were unclear or did not adequately report on sequence generation, allocation concealment and blinding. Missing data affected the assessment of incomplete outcome data, and selective reporting and other biases were also likely.
Effects of interventions
We included four studies ( 
Risk factor versus routine screening Primary outcomes
Significantly more women were diagnosed with GDM in the universal screening group than in the risk factor screening group (Griffin 2000). Thirty-five women were diagnosed with GDM in the routine screening group compared with 22 in the risk factor group (one trial, 3152 women, risk ratio (RR) 0.44, 95% confidence interval (CI) 0.26 to 0.75) (Analysis 1.1). The Griffin 2000 trial did not report on the other primary outcomes including: positive screen for GDM, mode of birth, largefor-gestational age and macrosomia.
Secondary outcomes
Infants of mothers in the risk factor screening group were born significantly earlier than infants of mothers in the routine screening group (one trial, 3152 women, mean difference (MD) -0.15 weeks, 95% CI -0.27 to -0.03) (Analysis 1.2). The remaining data from this trial were reported according to diagnosis of GDM and we have been in correspondence with the authors of this paper for additional data. Therefore, we have not been able to report data on any of the review's other secondary outcomes from this trial.
Glucose monomer versus glucose polymer Primary outcomes
Two studies, Bergus 1992 and Murphy 1994, compared a glucose monomer (d-glucose) with a glucose polymer drink for screening for GDM. No women were diagnosed with GDM in either group in Bergus 1992. Three women in the glucose monomer group and two women in the glucose polymer group were diagnosed with GDM in Murphy 1994. There was no significant difference in GDM diagnosis between groups overall (two trials, 161 women, RR 1.61, 95% CI 0.28 to 9.15) (Analysis 2.1). Numbers of women screening positive also showed no significant differences between groups in one trial (85 women, RR 2.36, 95% CI 0.90 to 6.21) (Analysis 2.2). These trials did not report on the other primary outcomes including: mode of birth, large-for-gestational age and macrosomia.
Secondary outcomes
Both trials reported a number of side effects from the method of glucose administration. Although not pre-specified, any symptom, sick, tired, taste and bloating were included as measures of acceptability of testing. Women in the glucose monomer group were significantly more likely to experience 'any symptom' than those in the glucose polymer group (two trials, 151 women, RR 2.80, 95% CI 1.10 to 7.13). There was significant heterogeneity in this result, with an I² value of 61%, and thus a random-effects meta-analysis was used (Analysis 2.3). Nausea was experienced significantly more often by women in the glucose monomer group than glucose polymer (two trials, 151 women, RR 2.62, 95% CI 1.01 to 6.79). No statistically significant differences were found for all other measures of acceptability of testing, including: dizziness and abdominal discomfort (both trials); bloating (Murphy 1994); headache, vomiting, sickness and tiredness (Bergus 1992); or taste (Murphy 1994) (Analysis 2.4). Neither study reported on additional maternal or infant secondary review outcomes.
Glucose monomer versus candy bar Primary outcomes
Murphy 1994 included a third group of women, who consumed a chocolate bar as an alternative to the two types of glucose drinks. There was no significant difference in diagnosis of GDM between the candy bar and glucose monomer groups, with three women diagnosed with GDM in the glucose monomer group, compared with none in the candy bar group (one trial, 80 women, RR 6.67, 95% CI 0.36 to 125.02) (Analysis 3.1). However, significantly more women in the monomer group screened positive for GDM (RR 3.49, 95% CI 1.05 to 11.57) (Analysis 3.2). This trial did not report on the other primary outcomes including: mode of birth, large-for-gestational age and macrosomia.
Secondary outcomes
The candy bar was given the highest rating for taste significantly more often than glucose monomer (one trial, 80 women, RR 0.35, 95% CI 0.17 to 0.74) (Analysis 3.3). No significant differences were seen overall (RR 1.90, 95% CI 0.97 to 3.72) or for each individual symptom of dizziness, nausea, abdominal discomfort and bloating (Analysis 3.4). No other maternal or infant secondary review outcomes were reported by this trial.
Glucose polymer versus candy bar Primary outcomes
No significant difference was found in diagnosis of GDM between the two groups (glucose polymer versus candy bar) (one trial, 83 women, RR 4.44, 95% CI 0.22 to 89.84) (Analysis 4.1) or for screening positive (RR 1.48, 95% CI 0.38 to 5.78) (Analysis 4.2). This trial did not report on the other primary outcomes including: mode of birth, large-for-gestational age and macrosomia.
Secondary outcomes
Again, the candy bar was preferred for taste significantly more often than the glucose polymer drink (one trial, 83 women, RR 0.42, 95% CI 0.22 to 0.82) (Analysis 4.3). Other measures of acceptability of testing were not significantly different between the two groups (RR 0.39, 95% CI 0.13 to 1.18) (Analysis 4.4). No other maternal or infant secondary review outcomes were reported by this trial.
Glucose solution versus food Primary outcomes
In one trial (Martinez Collado 2003), there was no significant difference in having a positive screening test for GDM between the two glucose solution and food mix groups (30 women, RR 7.00, 95% CI 0.39 to 124.83) (Analysis 5.1).
This trial did not report on the other primary outcomes including: diagnosis of GDM, mode of birth, large-for-gestational age and macrosomia.
Secondary outcomes
Women receiving the glucose solution were more likely to experience a side effect of the screening, including nausea, vomiting, migraine, diarrhoea and feeling sick, than those receiving the food mix (80% versus 7% for 'any symptom', one trial, 30 women, RR 12.00, 95% CI 1.78 to 81.06) (Analysis 5.2). No other maternal or infant secondary review outcomes were reported by this trial. There were insufficient data to perform subgroup analyses or sensitivity analyses for all comparisons of the review.
D I S C U S S I O N
Gestational diabetes mellitus (GDM) is widely accepted as a serious health issue, associated with serious maternal and infant morbidity. Recent, high-quality evidence exists to suggest that treatment of GDM is beneficial (Crowther 2005; Landon 2009). The variation in screening practices and guidelines, both in national surveys and worldwide, further demonstrates the need for large, high-quality trials evaluating the effect of screening for GDM (ACOG 2001; ADA 2003; CDA 2008; Gabbe 2004; Hanna 2008; Mires 1999; NICE 2008; Oats 2004; RANZCOG 2008; Rumbold 2001) . Despite its use, this review found little evidence on the effect of screening on maternal and infant health outcomes. This is consistent with other reviews on screening for GDM (Hillier 2008; Hollander 2007; NICE 2008; Scott 2002) .
We included four trials evaluating various methods of screening for GDM, which can be considered in two categories. Griffin 2000 evaluated different screening protocols. Bergus 1992, Martinez Collado 2003 and Murphy 1994 compared different types of glucose for a 50 g OGCT.
Griffin 2000 was a large quasi-randomised trial comparing universal screening by 50 g OGCT with risk factor screening and reported on diagnosis of GDM, positive screening for GDM and gestational age at birth. Of the 1299 women in the universal screening group who completed an OGCT, 366 were referred for an oral glucose tolerance test (OGTT). By comparison, fewer women (249 of the 1853 women in the risk factor group) were referred for an OGTT. Unsurprisingly, with more women offered diagnostic testing for GDM in the universal screening group, more women were diagnosed with GDM. It is, however, difficult to interpret how these increases in diagnoses and subsequent management translate to clinical maternal and infant health outcomes in the review. The marginal reduction seen in gestational age at birth is likely a result of the large sample size rather than a clinically relevant difference.
The trial reported on the remaining health outcome data with women reorganised into three groups, those who were not diagnosed with GDM, women who were diagnosed with GDM from the universal screening group and those diagnosed with GDM in the risk factor screening group.
While more women received glucose testing in the universal screening group, compared to those in the risk factor group, Griffin 2000 did not report on women's views on the two forms of screening. In addition to side effects of receiving a glucose load, practical issues for testing and the anxiety from screening and false positive results, the anxiety created by receiving an abnormal result on screening compared with receiving information on background risk of GDM is also important in selecting an appropriate screening protocol. Women's views on their health status and the screening protocol would be further affected by whether or not they are subsequently diagnosed and managed for GDM. Given that some screening protocols will result in more women being diagnosed with GDM than others, this may influence women's views on their health status.
Furthermore, although management of diagnosed GDM improves maternal and infant health outcomes, the diagnosis of GDM may also be associated with increased intervention or monitoring such as induction of labour and neonatal intensive care unit admission (Alwan 2009). Therefore, with various protocols for screening, the subsequent management of women with a positive or negative screening result as part of these protocols may impact on maternal and infant health. Large studies are required to address these issues and given that only a proportion of women are subsequently diagnosed with GDM, these trials require sufficient power for subgroup analyses by diagnosis of GDM are meaningful.
Interestingly, women in the risk factor group with risk factors for GDM received an oral glucose tolerance test at 32 weeks. Women in the universal screening group underwent a glucose challenge test at 26 to 28 weeks' gestation and were referred for subsequent OGTT if this was positive. Further to this, if glucose testing was negative, repeat screening was performed where the woman had risk factors for GDM. The risk factor group is therefore more likely to be diagnosed at a later stage in pregnancy than those in the universal screening group. It is unclear, however, if the timing of glucose testing has affected health outcomes.
The trials (Bergus 1992; Martinez Collado 2003; Murphy 1994) evaluating different types of glucose for the challenge test were primarily interested in the side effects and number of women diagnosed by different forms of glucose. Therefore, unlike Griffin 2000, the women in these trials were all offered the same diagnostic testing pathway regardless of the screening result. Although no health outcome data were included in the review, data on health outcome would be unlikely to be affected by the screening test because the women received the same subsequent management.
Bergus 1992 and Murphy 1994 included a comparison of glu-cose monomer (d-glucose) and glucose polymer. Overall, fewer side effects were reported by women receiving a glucose polymer drink than glucose monomer. There was, however, significant heterogeneity in this result, with a stronger effect seen in Murphy 1994 than Bergus 1992. This may be explained by the different approaches taken by the trials, with Murphy 1994 only reporting side effects where they were rated moderate to severe. Bergus 1992 however used a binary approach. The differences in data presentation therefore limit interpretation of these outcomes. Maternal and infant health outcomes were not recorded by the trials. Although not statistically significant, the glucose polymer group generally reported fewer side effects in the moderate to severe range than the candy bar group.
Interpretation of the results of this arm of the review are, however, limited by the number of participants in each trial. Although women were screened at 24 to 28 weeks' gestation in the trials, Murphy 1994 also included women in their first trimester with risk factors for GDM and Martinez Collado 2003 included women with a 'high-risk' pregnancy. Both trials used a 100 g OGTT for diagnosis of GDM.
The results of this review were limited by the number of participants and methodological quality of the trials, which, overall, was assessed to be moderate to low. Therefore, the results of this review are to be interpreted with caution. Bergus 1992, Martinez Collado 2003 and Murphy 1994 included a total of 230 women and were both primarily interested in the side effects and numbers of women diagnosed by different forms of glucose. As a consequence, most of the maternal and infant health outcomes included in this review were not reported by these trials. While Griffin 2000 was a large quasi-randomised trial enrolling 3792 women, the format of outcome reporting precluded the outcome data of interest for this review from being included.
The trials included in this review were conducted in the United States, Ireland and Mexico. Geographical location, socio-economic circumstances and ethnicity are important factors that can alter the most appropriate method of screening with regard to feasibility and practicality. Compliance is probably not only related to side effects, as investigated by Bergus 1992, Martinez Collado 2003 and Murphy 1994, but also the requirements for the screening protocol. For example, the inconvenience posed by a one-hour 50 g OGCT should be considered against random capillary blood glucose testing or risk factor screening. This emphasises the need for future research to report not only on subsequent management and maternal and infant health outcomes, but also on the acceptability of and adherence to particular screening protocols.
One trial (Bebbington 1999) published as an abstract, and awaiting assessment, also compared universal and selected screening in 2401 women with no reported risk factors for GDM. In abstract form, there were insufficient data to include results in the review. The abstract reports no significant difference in birthweight and the incidence of macrosomia between the two groups.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There was insufficient evidence from this review to determine the effects of screening for GDM and its subsequent management, or the comparative effects of different protocols for screening.
Although women who were routinely screened by 50 g glucose challenge testing were more likely to be diagnosed with GDM than those screened by their risk factors, effects of subsequent management on health outcome are unclear.
Implications for research
Large, high-quality trials are required to evaluate the effects of screening and subsequent management of GDM. As only a proportion of women will be subsequently diagnosed with GDM in these trials, a large number of participants is required for sufficient power to detect statistically significant differences and subgroup analyses by diagnosis. Future studies should assess the value of screening compared with no screening in addition to comparing different types of screening tools. The 50 g oral glucose challenge test and screening tools that are more easily implemented such as risk factor screening, glucosuria and the use of capillary blood glucose testing need to be evaluated as part of screening protocols. Furthermore, assessment of the optimal gestational age for screening is required. Trials should include data on health outcomes for mother and baby, acceptability of the screening protocol and cost effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Bergus 1992
Methods Randomised controlled trial. Funding: unspecified.
Participants Location: Ketchikan Native Health Clinic, Ketchikan, Alaska and Mt. Edgecumbe Hospital, Sitka, Alaska Inclusion criteria: pregnant native Alaskan women at 24-28 weeks' gestation, with no history of diabetes mellitus, between January 1988 and May 1990 Exclusion criteria: none specified. 76 women were enrolled into the study.
Interventions
Participants received either a 50 g glucose monomer or 50 g glucose polymer according to their randomly allocated group, regardless of time of last meal Both groups: venous and capillary samples were collected after 1 hour. A result of greater than or equal to 7.8 mmol/L was considered positive. All participants underwent a 100 g 3-hour OGTT within 3 days of their glucose challenge test Outcomes Maternal: venous plasma glucose following glucose challenge test, capillary blood glucose following glucose challenge test, OGTT and symptom questionnaire ('felt sick', 'felt nauseated', 'headache', 'felt dizzy', 'felt bloated', 'felt tired', 'vomited' and 'felt abdominal discomfort') Infant: none.
Notes
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk 'Randomisation was achieved by using consecutive numbers from a random number table.'
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel (performance bias) All outcomes
Unclear risk 'Double-blind' implies that participants and personnel were blinded to randomised group, although this is not stated
Blinding of outcome assessment (detection bias) All outcomes
Unclear risk Blinding of outcome assessors was not reported.
Bergus 1992 (Continued)
Incomplete outcome data (attrition bias) All outcomes Unclear risk '10 women did not complete the symptom questionnaire, but their baseline characteristics did not differ significantly from those with complete data collection.' These women (13%) were excluded from the analysis of symptoms Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported.
Other bias Unclear risk Baseline characteristics were not reported. It is therefore, unclear whether baseline imbalances exist
Griffin 2000
Methods Quasi-randomised controlled trial. Funding: grant from Bayer Diagnostics and research grant from National Maternity Hospital, Dublin Participants Location: outpatient obstetric clinics at the National Maternity Hospital, Dublin Inclusion criteria: first visit to outpatient clinic of National Maternity Hospital, over a 24-month period Exclusion criteria: none specified. 3742 women were enrolled into the study, with 1853 randomised to the risk factor screening group and 1889 randomised to the universal screening group Interventions Risk factor group: 100 g 3-hour OGTT performed at 32 weeks' gestation if any risk factors are present (historical -first-degree relative with diabetes mellitus, > 100 kg in current pregnancy, previous baby > 4.5 kg, previous unexplained stillbirth/intrauterine death, previous major malformation, previous GDM, current -glycosuria in 2nd fasting urine sample, macrosomia in current pregnancy or polyhydramnios in current pregnancy) Universal group: 50 g 1-hour OGCT at 26-28 weeks' gestation without regard to time of last meal. This was considered positive if 1-hour plasma glucose was greater than or equal to 7.8 mmol/L. In those with a positive glucose challenge test, a 100 g OGTT was performed (using National Diabetes Data Group criteria). Women with risk factors for GDM (i.e. those listed for the risk factor group), had a repeat OGCT if the first OGCT was negative or if the OGTT was negative (following a positive OGCT) Both groups: there was uniform diabetic and obstetric management for all participants, regardless of randomly allocated screening group. Women diagnosed with GDM were referred to both an obstetrician and endocrinologist, reviewed every 2 weeks until 36 weeks and awaited until 42 weeks unless medically contraindicated. All participants diagnosed with GDM were instructed in appropriate diabetic diet and intensive insulin treatment was instituted if fasting and postprandial (1.5 hour) blood glucose following a standard breakfast were not maintained (< 5.9 mmol/L or < 7.9 mmol/L respectively) Outcomes Maternal: diagnosis of GDM, spontaneous vaginal birth at term, emergency caesarean section, pre-eclampsia and insulin treatment required Infant:
LGA, macrosomia (> 4500 g), hypoglycaemia, hyperbilirubinaemia, gestational
age at birth, ponderal index, admission to neonatal intensive care unit and preterm birth Notes We are in correspondence with authors for additional data. 
Risk of bias
Bias
Authors' judgement Support for judgement
Unclear risk
The allocation of participants is described as being 'randomly assigned', no further information is provided on the sequence generation Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel (performance bias) All outcomes Of the 124 women who were enrolled into the study, 44 were allocated to group 1 (glucose polymer), 41 were allocated to group 2 (d-glucose) and 39 were allocated to group 3 (candy bar). 16 of the 124 women were unable to complete the glucose tolerance test within 1 week of screening, as required by all participants. Of these 16 women, 5 vomited or were too symptomatic and 11 did not complete the glucose tolerance test for logistical reasons or incomplete data Interventions Those recruited, following hospital protocol, were screened at 24-28 weeks. Where the woman possessed 1 of the following risk factors, they also receive GDM screening at their initial visit (past history of glucose intolerance, first-degree relative with diabetes mellitus, age > 35 years, past macrosomia, habitual abortion, unexplained stillbirth, congenital anomalies or current pregnancy with glycosuria, hypertension, suspected LGA fetus, polyhydramnios or obesity). For each of the screening methods, the carbohydrate source was ingested without regard to time of last meal. Within 1 week of the screening test, all women were required to undergo a 100 g 3-hour glucose tolerance test (in 300 mL of carbonated water). GDM was diagnosed using O'Sullivan criteria Group 1 (n = 44): participants received 50 g of glucose polymer. This was made from 100 mL of 43% polymer solution with 1.5 g unsweetened flavouring and 50 mL of unsweetened club soda Group 2 (n = 41): participants received the standard 50 g d-glucose solution in 300 mL of carbonated water Group 3 (n = 39): participants received a total of 50 g of candy bar (containing milk chocolate, sucrose, corn syrup, partially hydrogenated soya bean oil, cocoa, salt, egg whites, malt extract, soybean protein and artificial flavour) 
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